Device type · MYF
Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
MYF
Microbiology
Device class
Class II
FDA decisions since 2015
5
510(k), De Novo and PMA
Adverse event reports
65
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2
- Product code
- MYF
- Device class
- Class II
- Review panel
- Microbiology
- Regulation
- 21 CFR 866.3305
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for MYF
Latest FDA decisions
K243575 · Decided Feb 12, 2025 · 85 days after receipt
Device type: Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2 (MYF) · Laboratory Medicine & Pathology
K220924 · Decided Oct 12, 2022 · 195 days after receipt
Device type: Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2 (MYF) · Laboratory Medicine & Pathology
K181514 · Decided Jun 13, 2019 · 370 days after receipt
Device type: Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2 (MYF) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Reports received
65
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
3
4.6% of reports
Injury reports
62
95% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 2 | 0 | 0 |
| Jan 24 | 1 | 0 | 0 | 0 |
| Feb 24 | 1 | 0 | 0 | 0 |
| Mar 24 | 1 | 0 | 0 | 0 |
| Apr 24 | 3 | 0 | 0 | 0 |
| May 24 | 2 | 0 | 0 | 0 |
| Jun 24 | 1 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 3 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 1 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 1 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 1 | 1 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 37 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 20 | 0 | 0 |
| Mar 26 | 1 | 5 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 1 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
- Diasorin62
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- False Positive Result63
- False Negative Result2
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions65
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- DiaSorin LIAISON HSV-2 Type Specific IgG, REF 310620Open, Classified
Z-0815-2024 · Started Dec 13, 2023 · Posted by FDA Jan 25, 2024
Reason given: DiaSorin has identified that lots 136344, 136344A, 136344B, 136344C, 136520, 136520A, 136520B, 136520C, 136604, 136703, 136703A, 136703B, 136703C 136775of LIAISON HSV-2 Type Specific IgG assay may produce increased equivocal and/or false positive results.
Cause as FDA categorized it: Under Investigation by firm
Siemens Healthcare Diagnostics, Inc
Z-1274-2021 · Started Feb 8, 2021 · Posted by FDA Mar 18, 2021
Reason given: Potential false positive HSV results. Siemens Healthcare Diagnostics, Inc. initiated a correction for ADVIA Centaur4P Herpes-2 lgG (HSV2) Onboard Stability and Calibration Frequency (Interval) Failures on the ADVIA Centaur XP System and ADVIA Centaur XPT System.
Cause as FDA categorized it: Under Investigation by firm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.